WCLC 2025 - Posters & ePosters-P2.08 .56 Sequencing of Chemoimmunotherapy in Resectable Locally Advanced NSCLC: Single Center Experience

P2.08 .56 Sequencing of Chemoimmunotherapy in Resectable Locally Advanced NSCLC: Single Center Experience

Pdf Summary

This retrospective single-center study evaluated the sequencing of chemoimmunotherapy (chemo-IO) in patients with resectable, locally advanced (stage II/III) non-small cell lung cancer (NSCLC). The study included 24 patients treated with either neoadjuvant chemoimmunotherapy (NCI) or adjuvant chemoimmunotherapy (ACI) from January 2018 to December 2023, excluding those with EGFR or ALK mutations. Chemoimmunotherapy is established as a standard treatment for this patient population, with neoadjuvant approaches gaining interest due to their biological rationale and demonstrated superiority in other cancers, such as melanoma.  <br /><br />Key findings showed no statistically significant differences in survival outcomes between the two treatment sequences. However, a trend was observed where the NCI group had a higher 3-year overall survival (OS) rate of 71% compared to 53% in the ACI group. Conversely, progression-free survival (PFS) at 3 years was 0% for NCI versus 51% for ACI, indicating better disease control with adjuvant therapy.  <br /><br />Due to the small sample size and retrospective design, these results are preliminary. The authors highlight the need for larger, prospective trials to definitively determine the optimal sequencing of chemoimmunotherapy in resectable NSCLC. Such studies, including the ongoing PROSPECT-Lung trial, are necessary to establish evidence-based guidelines.  <br /><br />In summary, while neoadjuvant chemoimmunotherapy shows a promising trend for improved overall survival, adjuvant treatment appears associated with better progression-free survival. Current data are insufficient to declare the superiority of either approach, underscoring the importance of further research in this evolving therapeutic area.

Asset Subtitle

Pranay Adavelly

Meta Tag

Speaker Pranay Adavelly

Topic Local-Regional Non-small Cell Lung Cancer

Keywords

chemoimmunotherapy

non-small cell lung cancer

NSCLC

neoadjuvant therapy

adjuvant therapy

overall survival

progression-free survival

retrospective study

PROSPECT-Lung trial

treatment sequencing